Improving cancer immunotherapies: Developing a novel antibody to CXCR2

改善癌症免疫疗法：开发 CXCR2 新型抗体

• 批准号: 104132
• 金额: $ 86.92万
• 依托单位: DJS ANTIBODIES LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104132
• 关键词: Improving; cancer; immunotherapies; Developing; novel

"DJS Antibodies has a novel technology which allows us to discover antibody therapeutics against previously intractable disease targets. We are utilising this technology to develop a new drug to treat colorectal and pancreatic cancers. In particular, our antibody will act alongside recently developed therapies which activate patients' immune systems to fight tumours. With over 16,000 deaths each year in the UK from colorectal cancer alone, there is a real need for the discovery of novel therapies, and this project directly addresses that need.The project details the work required to attain pre-clinical proof-of-concept, and show that an antibody against our target can reduce tumour growth in animal cancer models. To do this we must develop in parallel both our lead antibody, and a surrogate antibody which interacts specifically with model species' immune system.Over 24 months we will develop and test these antibodies directly contributing to the overall development of our lead drug. The output of the work will be a best-in-class therapeutic candidate and Innovate UK's support will expedite its progression toward the clinic and to having a positive impact on patients' lives."

“DJS Antibodies拥有一项新技术，使我们能够发现针对以前难以治疗的疾病靶点的抗体疗法。我们正在利用这项技术开发一种治疗结肠直肠癌和胰腺癌的新药。特别是，我们的抗体将与最近开发的激活患者免疫系统对抗肿瘤的疗法一起发挥作用。在英国，每年有超过16，000人死于结直肠癌，因此有真实的需要发现新的治疗方法，而该项目直接满足了这一需求。该项目详细介绍了实现临床前概念验证所需的工作，并表明针对我们目标的抗体可以减少动物癌症模型中的肿瘤生长。为此，我们必须同时开发我们的先导抗体和与模型动物免疫系统特异性相互作用的替代抗体。在24个月的时间里，我们将开发和测试这些抗体，这些抗体将直接促进我们先导药物的整体开发。这项工作的成果将是一流的治疗候选人，Innovate UK的支持将加快其向临床的进展，并对患者的生活产生积极的影响。"